VolitionRx Limited VNRX
0.20 USD +0.02 (+9.49%)
Nov 13, 2026, 9:35 AM EST
0.1935 Day range 0.205
0.17 52-week range 7.00
- YTD
- -96.12%
- 1 year
- -97.11%
News
benzinga.com VolitionRX Q3 EPS $(0.21) Beats $(0.40) Estimate, Sales $1.614M Beat $706.500K Estimate VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.40) by 47.5 percent. This is a 79 percent increase over losses of $(1.00) per…
prnewswire.com VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, November 13 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
prnewswire.com VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update Conference call to take place on Friday, November 13 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
benzinga.com VolitionRx Executes Non-Binding Letter Of Intent With Missionpharma A/S To Develop, Roll Out Volition's Prototype Lateral Flow Technology For NETosis VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent ("LOI") with Missionpharma A/S, a Danish global
benzinga.com VolitionRx Makes $500K Cash Partial Prepayment Towards Outstanding Principal Balance On Its Senior Secured Convertible Promissory Note Note dated January 15, 2026, in the original principal amount of $2,400,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the partial pre-payment, the remaining- benzinga.com VolitionRx Launches DETECSEPS Sepsis Detection Project With ~$7.3M French Government Funding French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of SepsisHENDERSON, Nev.,…
benzinga.com VolitionRx Fully Pays Off $7.5M Convertible Promissory Note, Dated May 20, 2025 VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-market session. The market value of their outstanding shares is at $4.0 million. Vivos Therapeutics…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's after-market session. The market value of their outstanding shares is at $144.8 million. TransCode…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) stock moved…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock…
benzinga.com Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings.…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers VolitionRX (AMEX:VNRX) shares increased by 102.2% to $0.69 during Thursday's pre-market session. The company's market cap stands at $4.8 million. NewcelX (NASDAQ:NCEL) shares increased by…
benzinga.com Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations VolitionRx reports 112% revenue growth in H1 2026 while advancing its Nu.Q diagnostic platforms across sepsis and oncology markets.
benzinga.com Why Salesforce Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket Salesforce Inc (NYSE: CRM) stock rose on good Q2 results and raised FY27 guidance, while other tech stocks saw gains in early trading.Salesforce (NYSE: CRM) jumps on strong Q2 results and raised…
benzinga.com VolitionRx Reports 112% H1 Revenue Growth, Advances Toward $5M Veterinary Milestone 112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic LeadersHENDERSON, Nev.,…
benzinga.com VolitionRx Announces Publication Of Peer-Reviewed Paper And Editorial Indicating That Its Nu.Q NETs H3.1 Biomarker Is An Independent Predictor Of 28-Day Mortality And Need For Renal Replacement Therapy In Sepsis And Septic Shock Patients Entitled "H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis—A Secondary Analysis of the SISPCT Randomized Control Trial1" and published in Critical Care Medicine, the…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.0 million. Summit Therapeutics…
benzinga.com VolitionRX Reports Q2 2026 Results: Full Earnings Call Transcript On Friday, VolitionRX (AMEX:VNRX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call…- benzinga.com VolitionRX Q2 EPS $(0.85) Misses $(0.57) Estimate, Sales $398.657K Miss $482.667K Estimate VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.57) by 49.12 percent. This is a 1316.67 percent decrease over losses of…
benzinga.com VolitionRx Announces That Results Utilizing Its Lateral Flow Prototype Are Highly Correlated With Results Utilizing Its Legacy Automated Nu.Q® NETs Test In Critically Ill Sepsis Patients This new lateral flow finger prick sample test could be used to rapidly identify high-risk patients in the ER or at the bedside, thereby greatly expanding the potential market beyond centralized lab…- benzinga.com VolitionRx Publishes Paper On The Prognostic Value Of Its Nu.Q Cancer Assay In Newly Diagnosed Lung Cancer Patients The clinical paper entitled "Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-world evidence1" has been written in conjunction with researchers and…
- benzinga.com VolitionRx Partners With Sysmex To Streamline Volition's Nu.Q NETs H3.1 Assay VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO:6869), a leader in global in vitro diagnostics, to optimize Volition's…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/- benzinga.com Full Transcript: VolitionRX Q1 2026 Earnings Call
benzinga.com VolitionRX Q1 EPS $(0.97) Misses $(0.75) Estimate, Sales $985.076K Beat $426.600K Estimate VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.75) by 29.33 percent. This is a 1516.67 percent decrease over losses of…
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com VolitionRx Submits Clinical Manuscript For Peer Review Over Its Nu.Q Vet Feline Prototype Assay To Trace Lymphoma In Cats VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline…
- benzinga.com VolitionRx Launches Online Store After 10 Years Of Research Into Cancer Testing Tools, Starts Selling Lab-Ready Nucleosome Products Online To Boost Research Use VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range of reliable, ready to use recombinant nucleosomes that we…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on VolitionRX, Lowers Price Target to $1 HC Wainwright & Co. analyst Yi Chen maintains VolitionRX (AMEX:VNRX) with a Buy and lowers the price target from $1.5 to $1.
- benzinga.com VolitionRX Q4 EPS $(0.05), Inline, Sales $447.034K Miss $765.167K Estimate VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.06) per share from the same period…
- benzinga.com VolitionRx Secures €2 Million Funding To Advance Nu.Q Diagnostics And Expand Access In Low-Income Markets VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2.3 million) in financing from Namur Invest ("NI") and…
- benzinga.com Earnings Scheduled For March 31, 2026
- benzinga.com VolitionRx Announces The Publication Of A New Clinical Manuscript Demonstrating That Nucleosome Levels, As Measured By Volition's Nu.Q H3.1 And Nu.Q H3R8 Citrulline Are Elevated In People That Have Experienced A Traumatic Event And Are Even Higher In Those Patients That Go On To Have Complications From The Trauma Peer Reviewed Clinical Study for Nu.Q® Biomarkers Published in Shock JournalHENDERSON, Nev., March 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics…
benzinga.com VolitionRx To Highlight Use Of Its Nu.Q Cancer Assays In Management Of Lung Cancer Patients At European Lung Cancer Conference VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com VolitionRx Achieves >99% Pure Tumor-Derived DNA Isolation With Novel ChIP-Seq Liquid Biopsy Technology, Advancing Early Cancer Detection Targets $36 Billion TAM in Early Cancer Detection and MRD.Company in active discussions with global diagnostic leaders to accelerate commercialization.HENDERSON, Nev., March 18, 2026 /PRNewswire/ --…
- benzinga.com VolitionRx Completes All Validation And Verification Of Chemiluminescent Immunoassay Version Of Nu.Q Vet Cancer Test With Fujifilm Vet Systems in Japan VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA)…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com VolitionRx To Highlight NETs Plasma Biomarker In Precision Medicine At EHSF Malta Conference Showing New Indication for Nu.Q® NETs HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session